DDInter1140 DDInter1435
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) ACHE
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
Mefloquine {u} (Compound) downregulates {v} (Gene) RRP12
Mefloquine {u} (Compound) causes {v} (Side Effect) Leukocytosis
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds ACHE (Gene)
Mefloquine (Compound) upregulates DDIT4 (Gene)
Mefloquine (Compound) downregulates RRP12 (Gene)
Mefloquine (Compound) causes Leukocytosis (Side Effect)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Mefloquine may lead to a major life threatening interaction when taken with Ibutilide
Mefloquine may lead to a major life threatening interaction when taken with Pimozide